Michael J Spinella

List of Publications by Year
in descending order

46 papers	2,131 citations	236925 25 h-index	233421 45 g-index
46 all docs	46 docs citations	46 times ranked	2355 citing authors

#	Article	IF	Citations
1	Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene, 2003, 22, 7305-7315.	5.9	297
2	Retinoic Acid Promotes Ubiquitination and Proteolysis of Cyclin D1 during Induced Tumor Cell Differentiation. Journal of Biological Chemistry, 1999, 274, 22013-22018.	3.4	139
3	Nestin Is Expressed in the Basal/Myoepithelial Layer of the Mammary Gland and Is a Selective Marker of Basal Epithelial Breast Tumors. Cancer Research, 2007, 67, 501-510.	0.9	116
4	Distinguishing between Folate Receptor-Î±-mediated Transport and Reduced Folate Carrier-mediated Transport in L1210 Leukemia Cells. Journal of Biological Chemistry, 1995, 270, 7842-7849.	3.4	106
5	Characterization of a Mutation in the Reduced Folate Carrier in a Transport Defective L1210 Murine Leukemia Cell Line. Journal of Biological Chemistry, 1995, 270, 22974-22979.	3.4	104
6	High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors. Cancer Research, 2009, 69, 9360-9366.	0.9	91
7	Developmentally-related candidate retinoic acid target genes regulated early during neuronal differentiation of human embryonal carcinoma. Oncogene, 2002, 21, 2880-2889.	5.9	87
8	A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma. Oncogene, 2005, 24, 6090-6100.	5.9	85
9	Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochemical Pharmacology, 1994, 47, 337-345.	4.4	67
10	pH Dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Biochemical Pharmacology, 1997, 53, 223-231.	4.4	64
11	Transcriptional Activation of the Nuclear Receptor Corepressor RIP140 by Retinoic Acid: A Potential Negative-Feedback Regulatory Mechanism. Biochemical and Biophysical Research Communications, 2001, 285, 969-975.	2.1	62
12	Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. Oncotarget, 2017, 8, 2949-2959.	1.8	57
13	Genesis, a Winged Helix transcriptional repressor, has embryonic expression limited to the neural crest, and stimulates proliferation in vitro in a neural development model. Cell and Tissue Research, 1999, 297, 371-382.	2.9	53
14	Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function. Oncogene, 2001, 20, 2559-2569.	5.9	51
15	Acute Hypersensitivity of Pluripotent Testicular Cancer-Derived Embryonal Carcinoma to Low-Dose 5-Aza Deoxycytidine Is Associated with Global DNA Damage-Associated p53 Activation, Anti-Pluripotency and DNA Demethylation. PLoS ONE, 2012, 7, e53003.	2.5	49
16	4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARÎ³ independent pathway. Oncogene, 1999, 18, 5747-5755.	5.9	44
17	G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program. Cancer Research, 2016, 76, 1204-1213.	0.9	42
18	Serine/Threonine Kinase 17A Is a Novel p53 Target Gene and Modulator of Cisplatin Toxicity and Reactive Oxygen Species in Testicular Cancer Cells. Journal of Biological Chemistry, 2011, 286, 19381-19391.	3.4	39

#	Article	IF	Citations
19	Cyclin Proteolysis as a Retinoid Cancer Prevention Mechanism. Annals of the New York Academy of Sciences, 2001, 952, 13-22.	3.8	38
20	Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors. , 2019, 2, 580-594.		35
21	Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. Oncogene, 1998, 16, 3471-3480.	5.9	34
22	Comparison of transport properties of the reduced folate carrier and folate receptor in murine L1210 leukemia cells. Biochemical Pharmacology, 1995, 50, 1287-1294.	4.4	33
23	Negative Feedback at the Level of Nuclear Receptor Coregulation. Journal of Biological Chemistry, 2003, 278, 43889-43892.	3.4	33
24	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. Oncogene, 1998, 17, 761-767.	5.9	31
25	Limiting Effects of RIP140 in Estrogen Signaling. Journal of Biological Chemistry, 2005, 280, 7829-7835.	3.4	29
26	Retinoid Target Gene Activation during Induced Tumor Cell Differentiation: Human Embryonal Carcinoma as a Model. Journal of Nutrition, 2003, 133, 273S-276S.	2.9	28
27	Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2. Gene, 2002, 291, 17-27.	2.2	26
28	Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors. Cancers, 2019, 11, 796.	3.7	25
29	Toward a Mechanistic Understanding of Poly- and Perfluoroalkylated Substances and Cancer. Cancers, 2022, 14, 2919.	3.7	25
30	Serine/Threonine Kinase 17A Is a Novel Candidate for Therapeutic Targeting in Glioblastoma. PLoS ONE, 2013, 8, e81803.	2.5	24
31	Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells. Current Cancer Therapy Reviews, 2006, 2, 255-270.	0.3	23
32	A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer. Cancer Medicine, 2021, 10, 156-163.	2.8	23
33	Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours. Epigenetics, 2021, 16, 1071-1084.	2.7	21
34	Modulation of Clock Gene Expression by the Transcriptional Coregulator Receptor Interacting Protein 140 (RIP140). Journal of Biological Rhythms, 2011, 26, 187-199.	2.6	18
35	Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors. Cancers, 2021, 13, 1506.	3.7	18
36	Comparison of methotrexate polyglutamylation in l1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Biochemical Pharmacology, 1996, 52, 703-712.	4.4	17

#	Article	IF	Citations
37	The potential of retinoids for combination therapy of lung cancer: Updates and future directions. Pharmacological Research, 2019, 147, 104331.	7.1	16
38	G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. Cell Cycle, 2017, 16, 2146-2155.	2.6	15
39	p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53. Oncogene, 2005, 24, 1481-1490.	5.9	14
40	Aberrant Retinoid Signaling and Breast Cancer: the View From Outside the Nucleus. Journal of the National Cancer Institute, 2000, 92, 438-440.	6.3	11
41	Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy. Molecular Oncology, 2022, 16, 683-698.	4.6	10
42	All-trans-retinoic acid antagonizes the hedgehog pathway by inducing patched. Cancer Biology and Therapy, 2014, 15, 463-472.	3.4	9
43	Retinoic Acid Mediates Long-Paced Oscillations in Retinoid Receptor Activity: Evidence for a Potential Role for RIP140. PLoS ONE, 2009, 4, e7639.	2.5	8
44	Endothelin-receptor interactions. FEBS Letters, 1993, 328, 82-88.	2.8	6
45	Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review. Targeted Oncology, 2018, 13, 49-60.	3.6	5
46	Headway and Hurdles in the Clinical Development of Dietary Phytochemicals for Cancer Therapy and Prevention: Lessons Learned from Vitamin A Derivatives. AAPS Journal, 2014, 16, 281-288.	4.4	3